Isthmin (ISM) is a recently identified 60 kDa secreted angiogenesis inhibitor. Two cell-surface receptors for ISM have been defined, the high-affinity glucose-regulated protein 78 kDa (GRP78) and the low-affinity avb5 integrin. As avb5 integrin plays an important role in pulmonary vascular permeability (VP) and ISM is highly expressed in mouse lung, we sought to clarify the role of ISM in VP.
Introduction
Isthmin (ISM) is a recently discovered angiogenesis inhibitor that acts on endothelial cells (ECs) through receptors avb5 integrin and glucose-regulated protein 78 kDa (GRP78). 1, 2 It is a 60 kDa secreted protein first identified as part of the Fgf8-synexpression group in the Xenopus midbrain -hindbrain boundary. 3 ISM contains a centrally located thrombospondin type 1 repeat (TSR) and a C-terminal adhesion-associated domain in MUC4 and other proteins (AMOP) domain. The TSR domain is known to be involved in cell -cell and cellmatrix interactions, 4 while the AMOP domain is speculated to be involved in cell adhesion due to its presence in cell-adhesion molecules. 5 We have previously shown that ISM influence both physiological and pathological angiogenesis. 1 Systemic administration of recombinant ISM inhibits tumour growth mainly by inducing apoptosis in both tumour ECs and tumour cells that express high cell-surface GRP78. 2 Importantly, ISM triggers apoptosis in target cells through its two cellsurface receptors in two independent signaling pathways. 2 The endothelium constitutes a single layer of ECs that serves as the barrier between the circulating blood and the surrounding tissues, maintaining homeostasis and regulating vascular permeability (VP). 6 It regulates the passage of circulating cells, plasma proteins and fluid to/from the interstitial space to supply tissues with nutrients and clearing waste products. This regulation is performed by the coordinated action of permeability inducers and inhibitors. Opening up of the endothelial barrier is a critical step in mediating physiological processes such as immune surveillance, inflammation as well as cancer, atherosclerosis, and other pathological conditions. 7 -9 We have previously reported that ISM functions as an integrin avb5 antagonist, possibly disrupting cell -matrix interactions. 10 Integrin avb5 is involved in the regulation of pulmonary VP in an acute lung injury (ALI) model. 11 Using neutralizing antibodies, it was shown that blocking avb5 integrin led to inhibition of VEGF-induced pulmonary permeability. Intercellular junctions are important regulators of VP. They are made up of cell-adhesion molecules that mediate direct cell -cell interactions, bind cells into tissues, and help in the maintenance of tissue integrity and cell -cell communication. In ECs, two types of junctions are present, the adherens junctions (AJ) and the tight junctions (TJ). However, unlike epithelial cells, the AJ and TJ in ECs are less defined. Along the cleft, AJ merge into TJ. The major players of the AJ are the cadherins; in ECs, specifically VE-cadherin. 12, 13 The tyrosine phosphorylation status of AJ molecules has been implicated in regulating VP. 14 The well-known permeability-inducing factor VEGF is known to cause dissociation of the AJ between ECs and thus allows movement of molecules across the endothelial barrier. 15 In this work, we report a novel function of ISM as a VP inducer. Mechanistic investigations revealed that ISM-induced VP relies on ISM-GRP78 interaction and Src kinase activation. Subsequent increase in phosphorylation of junctional proteins VE-cadherin, b-catenin, and p120 catenin leads to loss of these proteins in cell-cell AJ. Importantly, we also demonstrated for the first time that ISM induced direct GRP78-Src interaction, and this interaction likely prompted Src activation. Using a lipopolysaccharide (LPS)-induced ALI mouse model, we demonstrated that ISM is significantly up-regulated in ALI lung and contributes to the vascular hyperpermeability and oedema associated with ALI.
Methods

Cell lines and culture conditions
ECs used are human umbilical vein endothelial cells (HUVECs), human dermal microvascular endothelial cells (HMVEC-dermal) (Lonza), and human pulmonary microvascular endothelial cells (HMVEC-Lung) (ScienCell). HUVECs were isolated from fresh umbilical cords with informed consent from donors, according to the Declaration of Helsinki and approved by local Domain-Specific Review Board (DSRB) (protocol C/00/553). All ECs were cultured in EndoGro-LS (Millipore) supplemented with FBS and gentamycin (Sigma Aldrich) on pre-coated culture dishes/slides. All experiments were performed with cells from Passages 4 -8.
Animals
Animal care and experimentation was carried out following protocol approved by the local institutional animal care and use committee, which conform to NIH guidelines (IACUC protocol 066/12). Only female Balb/c mice were used in the experiments.
Recombinant proteins
rISM and rGRP78 were expressed in Escherichia coli and purified using Ni-NTA affinity chromatography followed by reverse-phase HPLC and confirmed to be endotoxin free. rSRC was purchased from Millipore.
In vitro EC monolayer permeability assay (FITC-dextran flux)
FITC-Dextran (average MW 2 000 000, Sigma Aldrich) flux across postconfluent EC monolayers was measured. Briefly, cells were seeded on precoated 1 mm transwell inserts (BD Biosciences) and grown to confluence. They were then starved in starvation media (EndoGro-LS without supplements + 2% FBS) for 3 h before subjected to different doses of ISM treatment. After treatment, FITC-dextran solution (0.4 mg/mL) was added to the upper chamber, and the inserts were shifted to another well with fresh media. Five minutes later, 0.1 mL of solution from the lower chamber was transferred to a 96-well plate, and fluorescence intensity at 485/530 nm was measured as permeability. In some experiments, the monolayer was treated with the pan-caspase inhibitor Z-VAD-fmk (Millipore), the Src kinase inhibitor PP1 (Sigma Aldrich), neutralization antibodies to avb5 (P1F76), or GRP78 (E-4, Santa Cruz Biotechnology) for 2 h prior to ISM treatment.
In vivo permeability assay
Local dermal permeability assays were performed on 8-to 10-week-old Balb/c mice as previously described. 16 Details are described in the Supplementary material online, methods.
Immunohistochemistry and immunocytochemistry
Tissue sections were stained with anti-VE-cadherin (Santa Cruz Biotechnology 
Immunoprecipitation and immunoblotting
Standard immunoprecipitation (IP) protocol was used. Cells were lysed with RIPA buffer containing protease inhibitors (Roche) and 2 mM phosphatase inhibitor sodium orthovanadate (Sigma Aldrich). Skin samples were lysed using urea lysis buffer containing protease and phosphatase inhibitors. About 0.5 -1 mg protein lysate was used in IP. Standard western blots were performed. In IP experiments, following binding with the primary antibody, residual lysate was collected and probed for b-actin for protein loading control. Band intensities were quantified using ImageJ software. Antibodies used are listed in the Supplementary material online, methods.
LPS-induced ALI in mice
LPS from E. coli (serotype O111:B4; Sigma Aldrich) was delivered intratracheally as previously described, 19 after the mice were anaesthetized with 2% isoflurane (Baxter), while control mice received saline in a similar fashion. Lung permeability was assessed by injecting Evans Blue dye 20 min before sacrificing the animals by CO 2 asphyxiation and by dye extraction from the lungs as described above. Bronchoalveolar lavage (BAL) fluid was collected by flushing the lungs with saline 24 h post LPS challenge. Lungs were harvested for protein analysis by western blotting as well as fixed for immunohistochemistry (IHC). For antibody neutralization study, 5 mg/kg of anti-GRP78 (Santa Cruz Biotechnology) or isotype control (Novus Biologicals) was injected intraperitoneally 24 h before LPS challenge. Lung permeability was then determined.
Statistical analysis
Statistical analyses between two groups were performed by Student's t-test and between multiple groups using one-way ANOVA. The sample size is indicated in the respective figure legends. A P-value of ,0.05 was considered significant in all cases (*P , 0.05). Error bars represent SD for in vitro experiments and SEM for in vivo experiments.
Results
ISM induces EC monolayer permeability in a dose-and time-dependent manner
To examine whether ISM influences EC permeability, ECs were grown to confluence on multi-well inserts and treated with recombinant ISM.
ISM-induced HUVEC monolayer permeability in a dose-dependent manner as measured by FITC-dextran (average MW 2 000 000) flux across the post-confluent monolayers over a period of 16 h ( Figure 1A ). Significant increase in dextran flux was observed at 100 nM. Using a concentration of 1 mM, a time-course analysis was performed. ISM increased FITC-Dextran flux at time points ≥2 h following exposure, with time-dependent increase in permeability up to 16 h (end of experiment) ( Figure 1D ). Similarly, ISM also induced dose-and time-dependent increases in dermal microvascular (HMVEC-dermal) and lung microvascular (HMVEC-Lung) monolayer permeability ( Figure 1B , C, E, and F ). As ISM is highly expressed in mouse lung, it may play a role in regulating pulmonary VP (see Supplementary material online, Figure S1 ). 20 
ISM induces VP in vivo
To test whether ISM induces VP in vivo, a Miles assay was adopted. Balb/c mice systemically injected with Evans Blue dye were subjected to intradermal injections of different doses of ISM and saline controls. ISM enhanced local dermal permeability in a dose-dependent manner within 15 min of intradermal injection ( Figure 2A and B).
To study whether ISM triggers VP systemically, we administered ISM via tail vein and analysed dye extravasation in multiple organs of mice ( Figure 2C -E). Organs were harvested at 15 min, 30 min, 1 h, 3 h, 6 h, 12 h, and 24 h post ISM administration, and dye extraction was carried out. Significant dye leakage from lung was first observed at 15 min after ISM administration and peaked at 1 h, by which time there was also a significant increase in stomach permeability ( Figure 2C and data not shown). Subsequently, pulmonary permeability gradually declined and returned to basal level by 24 h ( Figure 2C ). ISM did not induce any observable VP in kidney, liver, or heart in all the time points investigated ( Figure 2E and data not shown). These results indicate that ISM not only induces dermal permeability following a local delivery, it also induces pulmonary VP when systemically introduced into the blood circulation.
ISM triggers tyrosine phosphorylation and loss of AJ proteins from cell -cell junctions
Increased tyrosine phosphorylation of the intercellular adhesion molecules have been implicated in increased paracellular permeability.
14 Upon exposure to permeability regulators, monolayers undergo changes in tyrosine phosphorylation of junctional proteins, especially AJ proteins. To understand how ISM induces permeability, tyrosine phosphorylation of post-confluent EC monolayer was analysed using immunocytochemistry. Following serum starvation, ECs showed minimal tyrosine phosphorylation of junctional molecules, corresponding to tight intact boundaries. Exposure to ISM for 2 h led to a considerable increase in tyrosine phosphorylation in EC monolayer, particularly in cell -cell junctions ( Figure 3A , thick white arrows). The AJs of ECs are predominantly composed of vascular endothelial cadherin (VEcadherin). 12 The integrity of the AJs is critical for maintaining the endothelial barrier and VP. Disruption of VE-cadherin homophilic interactions leads to loosening of cell -cell adhesions and an increase in paracellular permeability. VEGF/VPF is known to induce permeability by causing loss of VE-cadherin from cell junctions. 21 In post-confluent HUVEC monolayers, VE-cadherin is localized to cellular junctions with the formation of strong homophilic adhesions. Exposure to ISM reduced VE-cadherin staining at cellular junctions and VE-cadherin staining became discontinuous and occasionally disappeared from cellular boundaries ( Figure 3A , middle panels). Loss of VE-cadherin from cell -cell junctions is time dependent, corresponding to the time-dependent increase in permeability (see Supplementary material online, Figure S2A ). 'Gaps' of VE-cadherin cell boundary appeared in the monolayer upon ISM exposure ( Figure 3A , thin white arrows). In addition, b-catenin, the cytoplasmic partner of VE-cadherin, was also lost from the junctions ( Figure 3A , bottom panels).
Corresponding to the loss of VE-cadherin and b-catenin from intercellular junctions, ISM induced a time-dependent increase in phosphorylated Y 658 of VE-cadherin starting from 3 h post exposure, with significant increase observed at 6 and 16 h post ISM treatment ( Figure 3B ). Figure 3B ). Furthermore, exposure to ISM led to a dose-dependent increase in phosphorylation of the cytoplasmic partners of VE-cadherin, b-catenin, and p120 catenin, at 6 h post ISM exposure, a time-point when significant increase in VP was observed ( Figure 3C) . Similarly, induction of dermal VP by ISM is accompanied with enhanced VE-cadherin and b-catenin phosphorylation in mouse skin ( Figure 3D ). Thus, ISM induces permeability by triggering tyrosine phosphorylation of adherent junctional proteins and loss of these junctional proteins from cell-cell junctions.
ISM induces VP through Src activation as well as apoptosis induction
One of the EC-surface receptors for ISM, integrin avb5, plays a critical role in pulmonary VP. 11 Meanwhile, the cytoplasmic Src kinase is a known mediator of integrin activity and VP. 24 -26 We therefore investigated whether Src is involved in ISM-induced VP. In cultured ECs, ISM potently activated Src (detected by the level of phosphorylated Src 416 )
( Figure 4A) . Meanwhile, activation of FAK, marked by phosphorylated FAK 397 , another integrin activity mediator, was not detected (data not shown). When Src activation was inhibited by the chemical inhibitor PP1 at 6 h post treatment, a time point when apoptosis has yet to fully manifest, 90% attenuation of ISM-induced permeability was observed. In comparison, at 16 h post ISM treatment, a time point when ISM induced apoptosis is well manifested, blocking Src activation reduced ISM-induced permeability only by 60% ( Figure 4B ).
To resolve whether ISM-induced VP represents a passive secondary effect of cells dying due to apoptosis and creating gaps, we compared the in vitro dynamics of ISM-induced permeability, Src activation, and apoptosis. Significant permeability can be observed at 2 h post ISM treatment (Figure 1) . Meanwhile, Src activation can also be observed within 2 h post ISM induction and pY416Src peaks at 6 h after which it gradually declines to basal level by 24 h ( Figure 4A ). In comparison, ISM-induced apoptosis took much longer to manifest with little apoptosis observed at 6 h post treatment when measured by DNA fragmentation ( Figure 4E ). Apoptosis only became significant at 16 h post treatment and reached higher level at 24 h. Hence, at early time points post ISM treatment, ISM induced permeability through Src activation rather than apoptosis induction.
Furthermore, in vivo ISM induced dermal and pulmonary VP both within 15 min after exposure (Figure 2) . At this time point, Src has been activated in the local dermis ( Figure 4A ) while apoptosis is unlikely to have manifested. These results indicate that ISM induces VP through Src activation independent from apoptosis.
On the other hand, at later time points (16 h or later) post ISM treatment, apoptosis indeed contributes to a significant portion of ISM's pro-permeability effect. As shown in Figure 4D , inhibiting apoptosis using Z-VAD-fmk suppressed .60% of ISM-induced permeability at 16 h compared with only 30% at 6 h post ISM treatment. Correspondingly, pre-treatment of EC monolayers with Z-VAD-fmk for 30 min partially restored ISM-induced VE-cadherin and b-catenin to cell -cell junctions (see Supplementary material online, Figure S2B ).
When Src activation was inhibited by PP1, apoptosis induction by ISM was not affected ( Figure 4C) . In fact, PP1 alone induced apoptosis (G) ISM-induced permeability can be reversed after ISM withdrawal more readily at 6 h (83%) than at 16 h (58%). HUVEC monolayers were treated with ISM in full growth media for 6 (or) 16 h following which ISM was removed and replaced with fresh media for another 16 h (n ¼ 3). *P , 0.05 by one-way ANOVA; ns, not significant. and contributed to the total apoptosis when ISM and PP1 were both present. Since PP1 potently suppressed ISM-induced permeability ( Figure 4B ), this further proves that ISM triggered VP via Src activation independent of apoptosis induction.
In addition, ISM-induced VP can almost be completely reversed upon its withdrawal after 6 h treatment. In contrast, when ISM withdrawal occurred after 16 h treatment, VP can only be reversed 50% ( Figure 4G) . These results suggest that Src-mediated VP can be reversed upon ISM withdrawal, but apoptosis-mediated VP cannot be reversed even after ISM withdrawal.
Altogether, we conclude that ISM induces VP directly through Src activation and indirectly via apoptosis induction.
ISM induces permeability through both cell-surface receptors
Previously, we have shown that antibody neutralization of either integrin avb5 or GRP78 inhibited ISM-induced apoptosis. 1, 2 To decipher which ISM receptor mediates its permeability-inducing activity, we used antibody neutralization to block integrin avb5 or GRP78 individually in EC monolayer permeability assays. While blocking avb5 did not have a significant effect on the basal permeability, it partially attenuated ISM-induced permeability in an anti-avb5 dose-dependent manner ( Figure 5A ). Interestingly, blockage of GRP78 by neutralizing antibody also dose-dependently attenuated ISM-induced permeability, with high anti-GRP78 doses almost completely blocking the induced permeability ( Figure 5B) . Thus, ISM induces permeability through signals mediated by both avb5 and GRP78 receptors.
ISM induces Src activation through GRP78
Since Src activation by ISM is required for ISM's permeability induction activity, we studied which ISM receptor mediated Src activation. As shown in Figure 5C , blocking cell-surface GRP78 attenuated ISM-induced Src activation. On the other hand, no effect on ISM-induced Src activation was observed when avb5 integrin was blocked by antibody ( Figure 5D ). In comparison, antibody blocking of avb5 integrin generated a partial inhibition of ISM-induced permeability ( Figure 5A ). Thus, ISM activates Src through cell-surface GRP78 but not avb5 integrin. ISM binding with cell-surface GRP78 is known to trigger ISM-GRP78 complex internalization via clathrin-dependent endocytosis. 2 Inhibition of clathrin-dependent endocytosis with chlorpromazine also attenuated ISM-induced permeability and Src activation in a dose-dependent manner ( Figure 5E and F ) . However, inhibiting Src activation using PP1 had no effect on ISM internalization ( Figure 5G) . Thus, ISM-induced Src activation and permeability require the ligation of ISM to GRP78 and its subsequent internalization, but Src activation is not required for ISM-GRP78 endocytosis.
ISM exposure induces/enhances direct GRP78 interaction with Src
Although GRP78 has been reported to function as a receptor kinase, 27 -29 the interaction of cell surface GRP78 with intracellular partners has not been reported. Since ISM-induced Src activation is dependent on ISM binding to GRP78, a GRP78 receptor-mediated intracellular signal transduction is likely to ensue. To clarify whether GRP78 interacts with Src, we performed co-IP experiment with recombinant GRP78 and Src in vitro. No interaction between the two proteins was observed in the experimental conditions tested (data not shown). However, in the presence of ISM, GRP78-Src interaction was observed ( Figure 6A ). When anti-Src or anti-GRP78 antibody bound protein A/G beads were incubated with whole cell lysate from ISM-treated or control HUVECs, binding between GRP78 and Src was observed in both control and ISM-treated cell lysate. Notably, there was an obvious increase in GRP78-Src interaction in ISM-treated cell lysate ( Figure 6A ). We then analysed whether GRP78 and Src co-localize and interact intracellularly. Upon overexpression of GRP78-mCherry and Src-GFP in both HUVECs and HEK293Ts, a significant increase in GRP78 and Src co-localization was observed after 24 h exposure to ISM ( Figure 6B and C ) . To further prove that GRP78 and Src indeed interact directly, PLA, a method allowing visualization and quantification of specific protein interaction events in situ, was performed in both HUVECs and HEK293Ts co-expressing GRP78-mCherry and Src-GFP. PLA signal represents direct interaction between two proteins in their native state and location. Notably, PLA signals were observed in the cytosol only in ISM-treated cells but not in control cells, suggesting direct interaction between GRP78 and Src upon ISM treatment ( Figure 6D and E) . The interaction between ISM and GRP78 in the same experimental setting was used as a positive control. No interaction between ISM and Src was observed.
Based on these results, we conclude that ISM binding to cell-surface GRP78 triggers ISM-GRP78 complex internalization and elicits GRP78-Src interaction in the cytosol. This interaction is likely responsible for ISM-induced Src activation.
ISM is up-regulated and contributes to LPS-induced ALI and pulmonary hyperpermeability in mice
ALI is a condition triggered by systemic or local lung inflammation that involves pulmonary vascular hyperpermeability and oedema. 30 , 31 The cellular and molecular mechanisms of ALI-associated pulmonary hyperpermeability and oedema are not fully understood. Since ISM is expressed in the lung, and systemic infusion of rISM induced VP most potently in mouse lung (Figure 2) , we investigated whether ISM is involved in pathological pulmonary hyperpermeability using a mouse model of ALI induced by LPS. Mice were challenged with 50 mg LPS and a substantial increase in pulmonary permeability was observed within 24 h following LPS challenge ( Figure 7A ). Both lung tissue lysates as well as BAL fluid showed significant up-regulations of ISM in LPS-challenged mice compared with saline control (Figure 7B and C ) . ISM up-regulation was observed in both bronchial and alveolar epithelial cells ( Figure 7D) . Furthermore, systemic infusion of an anti-GRP78 antibody targeted to block ISM's high-affinity receptor led to significant attenuation of LPS-induced pulmonary hyperpermeability ( Figure 7E) . The same anti-GRP78 antibody also effectively attenuated ISM-induced endothelial monolayer permeability in vitro ( Figure 5B ). In comparison, isotype control IgM has no effect on LPS-induced lung hyperpermeability ( Figure 7E ). These data strongly suggest that ISM contributes to LPS-induced pulmonary hyperpermeability and oedema in ALI.
Discussion
In this work, we report a novel function of the angiogenesis inhibitor ISM as a VP inducer. We further showed that ISM is up-regulated upon intratracheal LPS challenge in mouse lung and provided evidence that it contributes to the pulmonary hyperpermeability and oedema of LPS-induced ALI. Furthermore, we revealed that ISM directly induces endothelial permeability through its receptor GRP78-mediated Src activation. Thus, ISM is a novel regulator of endothelial barrier function. Different angiogenesis inhibitors regulate VP in different manners. Thrombospodin-1 (TSP-1) induces tyrosine phosphorylation of AJ proteins such as VE-cadherin, g-catenin, and p120 to induce paracellular permeability of the endothelial barrier. 32 Similarly, semaphorin 3A
was found to induce VP by tyrosine phosphorylation of AJ proteins. 33 However, other angiogenesis inhibitors such as endostatin and angiostatin are known to reduce permeability stimulator-induced VP. 34, 35 ISM seems to be similar to TSP-1 and semaphorin 3A to both inhibit angiogenesis yet promote VP through stimulation of junctional protein phosphorylation including VE-cadherin, b-catenin, and p120 catenin ( Figure 3) . VE-cadherin, b-catenin, and p120 catenin are partners in a complex which hold VE-cadherin on the intercellular junctions. 36 Increased tyrosine phosphorylation of AJ proteins uncouple the catenins from the cadherins, leading to the disruption of endothelial barrier and opening of paracellular permeability 37 ( Figures 3 and 4) . ISM triggers junctional protein phosphorylation via Src activation. Based on the time course of events upon ISM exposure to endothelial monolayers, it appears that ISM first triggers Src activation, followed by Srcmediated phosphorylation of AJ proteins and subsequent dissociation of the AJ, resulting in barrier disruption. In parallel, ISM binding to GRP78 and avb5 on the EC cell surface both induces apoptosis through two independent pathways and contribute to enhancing VP. 2 Whether the two functions of ISM (antiangiogenesis and propermeability) can be segregated physiology or pathology remains to be fully explored. The role of Src in endothelial permeability has been well documented including its role in VEGF-induced permeability. 25, 26 Using Src kinase inhibitor PP1, we demonstrated that Src activation is the dominant trigger of ISM-induced endothelial permeability at early time point (6 h post ISM treatment). At later time point (16 h post treatment), ISM-induced apoptosis also indirectly contributed significantly to the enhanced permeability ( Figure 4) . Inhibiting apoptosis by the pan-caspase inhibitor Z-VAD-fmk reduced ISM-induced permeability much more extensively at 16 h compared with at 6 h post ISM treatment. This correlates with the time required for apoptosis to manifest as substantially more apoptosis was observed at 16 h than 6 h post ISM treatment ( Figure 4F ). Since ISM induces apoptosis through both of its cell-surface receptors, neutralizing antibody to either GRP78 or integrin avb5 leads to attenuation of ISM-induced permeability. However, only anti-GRP78 antibody suppresses ISM-induced Src activation ( Figure 5 ). Using multiple techniques such as co-IP, fluorescent co-localization by confocal microscopy imaging and PLA, we demonstrated that ISM stimulates a direct interaction between GRP78 and Src, leading to Src activation ( Figures 5 and 6) . This is the first report revealing that GRP78 activates Src via direct interaction with Src. A schematic illustration of how ISM induces VP is presented in Figure 8 .
The low-affinity ISM receptor integrin avb5 has been shown to play an important role in VEGF-mediated VP by activating Src and opening up the VE-cadherin-catenin barrier. 11, 24 However, integrin ligation triggered Src activation requires the Src substrate FAK to form a FAK-avb5 signaling complex which lead to VP. 24 Since ISM activates Src without activating FAK (data not shown), ISM seems to induce permeability not through the Src-FAK-avb5 pathway. The partial attenuation of ISM-induced permeability by neutralizing avb5 is likely due to the attenuation of apoptosis induced through ISM-avb5 integrin interaction as previously reported. 1, 10 How cell-surface GRP78 transmits signal intracellularly remains to be elucidated. Evidences of GRP78 autophosphorylation have been reported both in vitro and in vivo. 38, 39 Upon binding to its ligand a 2 M * , cell-surface GRP78 was shown to undergo tyrosine phosphorylation. 28 Binding of another ligand Cripto to cell-surface GRP78 is known to cause Src activation. 29 Lead exposure was shown to disrupt tight junctions at the blood-brain barrier via GRP78-mediated Src activation. 40 Recently, cell-surface GRP78 was identified as a signal receptor for oxidized phospholipids (OxPAPC) in human pulmonary artery ECs and human lung microvascular ECs, mediating endothelial barrier enhancement. 41 Binding of OxPAPC to GRP78 also leads to Src activation in ECs. Furthermore, ADAM15 promotes endothelial hyperpermeability in LPS-induced ALI likely via Src activation. 42, 43 Although these findings all suggested that ligation of cell-surface GRP78 may trigger a GRP78-Src intracellular signaling pathway, in this work we demonstrated for the first time that ISM (ligand) binding to GRP78 leads to a direct interaction of GRP78 with cytoplasmic Src, triggering Src activation ( Figure 6 ). ALI is a significant source of morbidity and mortality in critically ill patients. Owing to the complexity of the disease and our incomplete understanding of its pathophysiology and molecular mechanisms, effective treatment and prevention of ALI remain as unmet medical needs. Our work here suggest that ISM may be a new player in vascular hyperpermeability and oedema in ALI. Inhibiting ISM overexpression or function may be a useful therapeutic approach that is worth further investigation.
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Supplementary material is available at Cardiovascular Research online. (2) . VE-cadherin, b-catenin, and p120 catenin phosphorylation are induced, leading to disruption of VE-cadherin homophilic adhesion between cells (3). The endothelial barrier opens up and paracellular permeability is induced (4). Simultaneously, ISM binding to its receptors avb5 and GRP78 leads to EC apoptosis, which indirectly promotes VP.
